Parallel Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$60.3K Buy
2,988
+2,331
+355% +$47K ﹤0.01% 2015
2026
Q1
$12.9K Buy
657
+589
+866% +$14.4K ﹤0.01% 2642
2025
Q4
$1.82K Sell
68
-18
-21% -$464 ﹤0.01% 3155
2025
Q3
$2.29K Sell
86
-216
-72% -$5.58K ﹤0.01% 3016
2025
Q2
$6.93K Buy
302
+244
+421% +$6.05K ﹤0.01% 2622
2025
Q1
$1.68K Buy
58
+47
+427% +$1.5K ﹤0.01% 3027
2024
Q4
$408 Hold
11
﹤0.01% 3259
2024
Q3
$534 Hold
11
﹤0.01% 3172
2024
Q2
$440 Sell
11
-9
-45% -$373 ﹤0.01% 3111
2024
Q1
$878 Sell
20
-75
-79% -$3.87K ﹤0.01% 2960
2023
Q4
$5.88K Hold
95
﹤0.01% 2472
2023
Q3
$4.37K Hold
95
﹤0.01% 2545
2023
Q2
$5.46K Hold
95
﹤0.01% 2399
2023
Q1
$3.56K Buy
95
+82
+631% +$2.69K ﹤0.01% 2545
2022
Q4
$364 Hold
13
﹤0.01% 3095
2022
Q3
$0 Sell
13
-6
-32% -$196 ﹤0.01% 3119
2022
Q2
$1K Buy
19
+6
+46% +$214 ﹤0.01% 2690
2022
Q1
$0 Sell
13
-100
-88% -$2.84K ﹤0.01% 2944
2021
Q4
$3K Buy
113
+4
+4% +$82 ﹤0.01% 2544
2021
Q3
$2K Buy
+109
New +$2.13K ﹤0.01% 2644

Other funds holding AMPH

Parallel Advisors's AMPH Position: Q2 2026 in Review

Parallel Advisors increased its Amphastar Pharmaceuticals (AMPH) stake by 355% in Q2 2026, buying an estimated $47K and bringing the position to 2,988 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

Parallel Advisors first reported a position in AMPH in Q3 2021 and has held it in 20 quarters since. 82 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Parallel Advisors held 2,988 shares of Amphastar Pharmaceuticals worth $60.3K as of Q2 2026.
  • Parallel Advisors bought 2,331 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $47K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2015 holding.
  • Parallel Advisors first reported a position in Amphastar Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • 82 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.